MicroPort® Orthopedics Attends Elite Arthroplasty Course-EAC-ISKAA in India
Chandigarh, India - From October 5 to October 9, MicroPort® Orthopedics and MicroPort® Scientific India attended the Elite Arthroplasty Course-EAC-ISKAA, the largest orthopedic replacement congress in India, and invited Dr. Harbinder Chadha, a renowned orthopedic expert from US-based Scripps Mercy Hospital, to share his clinical experience in SuperPath™ Micro-posterior Total Hip Arthroplasty ("SuperPath™") and knee replacement in roadshow activities.
On October 5, Dr. Chadha visited Max Elite Hospital, one of the leading arthroplasty centers in India which performs 3,000 knee and 500 hip replacements in a year. Dr. Chadha had one-on-one meeting with Dr. Manuj Wadhwa and he explained the design rationale of the Advance® Medial Pivot Knee ("Advance®") and made a presentation on SuperPath™. Dr. Chadha performed one Advance® surgery in the departemnt and explained all the instruments of Advance® in details to the entire operation theater staff along with the junior doctors present there.
Dr. Chadha had series of interactive sessions with various top key opinion leaders ("KOLs") like Dr. Sandeep Gupta, Dr. (Prof.) Sudhir Garg, Dr. Vijay Goel, Dr. Bharat Modi, to name a few. He very nicely explained the concept of medial pivot knee and the surgical nuisances to achieve the best surgical outcome. On October 7, Dr. Chadha performed a live case of Advance®. It was very well appreciated by all the delegates present in the auditorium and the session was very well moderated by Dr. (Prof.) Rajesh Malhotra and Dr. Krishna Kiran.
On October 8, Dr. Chadha performed a live case of SuperPath™ total hip replacement ("THR"). It was very well appreciated by all the audiences and moderated by Dr. Krishna Kiran. The experts were deeply impressed by the unique advantages of SuperPath™ compared to traditional posterior approach and direct anterior approach, such as less intraoperative pain and fast return to function. Dr. Chadha very nicely handled all the questions about SuperPath™ and reiterated all the benefits of SuperPath™ for the patients.
On October 9, Dr. Chadha visited All India Institute of Medical Sciences ("AIIMS") in New Delhi which is one of the most prestigious medical institutes in India. He delivered talks on SuperPath™ and Advance®. Dr. Chadha had active interaction with the various faculty members of AIIMS, especially Dr. (Prof.) Malhotra who is the Head of Department at AIIMS. Dr. (Prof.) Malhotra is a very accomplished and recognized doctor worldwide for his contribution to the field of arthroplasty and the management of various bone & joint diseases.
The successful roadshow of Dr. Chadha along with a very strong presence in prestigious arthroplasty course will further enhance the awareness of MicroPort® Orthopedics brand in the India market. The excellent products and technologies showcased in these activities will build the confidence of KOLs in MicroPort® Orthopedics to lay a solid foundation for the company to promote SuperPath™, Advance® as well as other products and techniques in the local market.
About MicroPort®
MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.
For more information, please refer to: www.microport.com
Forward-Looking Statements
Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.
This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.
All rights reserved.
Copyright © 1998-2018 MicroPort Scientific Corporation
Source: http://www.microport.com